TY - JOUR
T1 - Melanoma molecular classes and prognosis in the postgenomic era
AU - Tremante, Elisa
AU - Ginebri, Agnese
AU - Lo Monaco, Elisa
AU - Frascione, Pasquale
AU - Di Filippo, Franco
AU - Terrenato, Irene
AU - Benevolo, Maria
AU - Mottolese, Marcella
AU - Pescarmona, Edoardo
AU - Visca, Paolo
AU - Natali, Pier Giorgio
AU - Giacomini, Patrizio
PY - 2012/5
Y1 - 2012/5
N2 - Gene expression profiling is a powerful method to classify human tumours on the basis of biological aggressiveness, response to therapy, and outcome for the patient, but its application in melanoma lags behind that of other cancers. From more than 100 articles available on the topic, we selected 14 focusing on patients' outcome. We review and briefly discuss salient findings, and list ten reasons why melanoma molecular classes are not yet used in clinical diagnosis and prognosis. The available evidence suggests that we are on the verge of creating a framework for the use of melanoma molecular classes in prognosis, but so far there is little consensus to put together informative diagnostic and prognostic gene sets.
AB - Gene expression profiling is a powerful method to classify human tumours on the basis of biological aggressiveness, response to therapy, and outcome for the patient, but its application in melanoma lags behind that of other cancers. From more than 100 articles available on the topic, we selected 14 focusing on patients' outcome. We review and briefly discuss salient findings, and list ten reasons why melanoma molecular classes are not yet used in clinical diagnosis and prognosis. The available evidence suggests that we are on the verge of creating a framework for the use of melanoma molecular classes in prognosis, but so far there is little consensus to put together informative diagnostic and prognostic gene sets.
UR - http://www.scopus.com/inward/record.url?scp=84860424628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860424628&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(12)70003-7
DO - 10.1016/S1470-2045(12)70003-7
M3 - Article
C2 - 22554548
AN - SCOPUS:84860424628
VL - 13
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 5
ER -